The newly tested blinatumomab precisely targets the cancer cells, offering a kinder alternative to chemotherapy, which damages normal cells in the body and leads to serious side effects.
BJN provides nurses with an evidence base for clinical practice and a platform for professional development. It shares the information and advice that is key to unlocking your full potential.
Clinical expertise
Peer-reviewed research
Best practice guidance
CPD support
